Cognitive and behavioral treatment programs for sexual offenders have become widespread during the past 10 years. Despite the proliferation of treatment programs and the advances made in the treatment of sexual offenders, many of these offenders remain a danger to society. As such, interest has peaked in medical approaches designed to reduce the risk posed by such offenders. The United States has historically shied away from the medical castration that is used in many European countries. Instead, the use of medications to reduce sex drive has been championed by many as a viable option, coupled with the continued use of cognitive and behavioral therapies. The authors review the current research literature pertaining to the use of three classes of drugs used to hamper the sex drive of male sexual offenders: (1) hormonal agents that act peripherally, such as depo-Provera, (2) hormonal agents that act centrally, such as Leupron, and (3) serotonin-active antidepressants, such as Prozac and Paxil. Also reviewed are the preliminary findings from an Oregon pilot program utilizing depo-Provera in a group of potentially dangerous sexual offenders. Findings basically show that it is too soon to ascertain whether medication will help reduce sexual recidivism among those enrolled in the program. Thus far, medication has not been shown to increase compliance with the supervision requirements of these offenders. In conclusion, the authors note that medications should be seen as temporary solutions while offenders continue to undergo cognitive and behavioral treatments. References